Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 18, 2023

FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment for BRAFV600E-Mutant Metastatic Colorectal Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
J. Clin. Oncol 2023 Jun 23;[EPub Ahead of Print], S Stintzing, K Heinrich, D Tougeron, DP Modest, I Schwaner, J Eucker, R Pihusch, M Stauch, F Kaiser, C Kahl, M Karthaus, C Müller, C Burkart, A Reinacher-Schick, S Kasper-Virchow, L Fischer von Weikersthal, B Krammer-Steiner, GW Prager, J Taieb, V Heinemann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading